IntelGenx Corp

Vetio Animal Health is a leading Contract Development and Manufacturing Organization (CDMO) focused on the advancement of animal health. With a commitment to Quality by Design, the company integrates product development with extensive manufacturing capabilities, addressing the needs of veterinary pharmaceutical products, pet nutrition supplements, and topical treatments. Utilizing a combination of innovative development, technical expertise, and advanced analytical services, Vetio aims to improve the lives of animals while ensuring the highest standards of safety, quality, and compliance. The company continues to expand its operations and product offerings, solidifying its role as a vital partner in the animal health industry. Generated from the website

Xstrata Zinc Canada, based in Saint-Laurent, QC, is a mining company that specializes in the extraction and production of zinc. With a focus on sustainability and efficiency, the company plays a key role in the global zinc industry. Committed to responsible mining practices, Xstrata Zinc Canada prioritizes safety and environmental stewardship in all aspects of its operations. Through ongoing innovation and dedication to quality, the company continues to be a leader in the zinc mining sector. Generated from their business information

Cyclenium Pharma Inc, based in Montréal, Québec, is the Canadian Subsidiary of SpiroChem AG, specializing in utilizing its proprietary CMRT™ small-molecule macrocycle technology for drug discovery against challenging disease targets. As a Contract Research Organization, Cyclenium provides solutions to pharmaceutical and biotechnology companies globally, enabling exploration of macrocycles as innovative modalities. Founded by experts from Tranzyme Pharma, pioneers in small molecule macrocycles for drug discovery, Cyclenium boasts a profound knowledge base in macrocyclic chemistry, developed from the generation and optimization of lead candidates that progressed to late-stage clinical trials. Their cutting-edge technology addresses previous limitations in the field, offering customers access to a revolutionary platform for drug discovery. Over the years, Cyclenium has achieved significant milestones, including collaborations with prominent organizations like Vuja De Sciences, AiCuris, and Ono Pharmaceutical, showcasing their expertise in areas such as anti-infective pharmaceuticals and pan-flaviviral therapeutics. With a team led by experienced professionals like CEO & CSO Thomas Fessard and Executive Director of Medicinal Chemistry Arkadii Vaisburg, Cyclenium continues to drive innovation in pharmaceutical research and development. Generated from the website content